Danaher (NYSE:DHR) Upgraded by StockNews.com to “Buy”
Danaher (NYSE:DHR – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Wednesday.
Several other equities research analysts also recently commented on the company. Royal Bank of Canada dropped their target price on Danaher from $246.00 to $239.00 and set an “outperform” rating on the stock in a report on Wednesday, October 25th. Barclays dropped their target price on Danaher from $290.00 to $215.00 and set an “overweight” rating on the stock in a report on Thursday, October 26th. JPMorgan Chase & Co. raised their target price on Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a report on Wednesday. The Goldman Sachs Group downgraded Danaher from a “buy” rating to a “neutral” rating and dropped their target price for the company from $215.00 to $205.00 in a report on Thursday, December 7th. Finally, Citigroup raised their target price on Danaher from $240.00 to $255.00 and gave the company a “buy” rating in a report on Monday, December 11th. Six investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $259.40.
Danaher Trading Down 1.0 %
Shares of NYSE DHR traded down $2.33 during midday trading on Wednesday, hitting $226.81. The stock had a trading volume of 2,673,112 shares, compared to its average volume of 3,234,584. The company has a market capitalization of $167.60 billion, a price-to-earnings ratio of 28.60, a PEG ratio of 2.27 and a beta of 0.84. Danaher has a 1-year low of $182.09 and a 1-year high of $247.62. The company has a quick ratio of 1.94, a current ratio of 2.26 and a debt-to-equity ratio of 0.37. The company has a fifty day moving average price of $210.12 and a 200 day moving average price of $233.19.
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings data on Tuesday, October 24th. The conglomerate reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.19. The business had revenue of $6.87 billion for the quarter, compared to analyst estimates of $6.60 billion. Danaher had a return on equity of 13.71% and a net margin of 20.01%. The company’s revenue was down 10.3% compared to the same quarter last year. During the same period in the previous year, the company posted $2.56 EPS. On average, analysts predict that Danaher will post 8.3 earnings per share for the current year.
Institutional Investors Weigh In On Danaher
Institutional investors and hedge funds have recently made changes to their positions in the company. Bank Julius Baer & Co. Ltd Zurich grew its stake in Danaher by 100,144.5% during the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,184,308,095 shares of the conglomerate’s stock worth $284,233,943,000 after buying an additional 1,183,126,676 shares during the last quarter. Moneta Group Investment Advisors LLC grew its stake in Danaher by 96,490.5% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 23,287,013 shares of the conglomerate’s stock worth $6,180,839,000 after buying an additional 23,262,904 shares during the last quarter. Norges Bank bought a new position in Danaher during the 4th quarter worth $2,057,164,000. Wellington Management Group LLP grew its stake in Danaher by 18.6% during the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after buying an additional 3,905,449 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Danaher by 66.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 5,997,282 shares of the conglomerate’s stock worth $1,439,348,000 after buying an additional 2,398,426 shares during the last quarter. 76.71% of the stock is owned by institutional investors and hedge funds.
About Danaher (Get Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions.
Recommended Stories
NYSE: DHR’ width=”650″ height=”330″ />
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Danaher, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Danaher wasn’t on the list.
While Danaher currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Original: MarketBeat News Feed: Danaher (NYSE:DHR) Upgraded by StockNews.com to “Buy”